Minnesota Statutes Insurance (Ch. 59A-79a) § 62Q.48. Cost-sharing in prescription insulin drugs

Subd. 2.Definitions. (a) For the purposes of this section, the terms defined in this subdivision have the meanings given them.

(b) “Cost-sharing” means a deductible payment, co-payment, or coinsurance amount imposed on an enrollee for a covered prescription drug in accordance with the terms and conditions of the enrollee's health plan.

(c) “Legend drug” has the same meaning as in section 151.01, subdivision 17.

(d) “Prescription insulin drug” means a legend drug that contains insulin and is used to treat diabetes.

(e) “Net price” means the health plan company's cost for a prescription insulin drug, including any rebates or discounts received by or accrued directly or indirectly to the health plan company from a drug manufacturer or pharmacy benefit manager.

Subd. 3.Cost-sharing limits. (a) A health plan that imposes a cost-sharing requirement on the coverage of a prescription insulin drug shall limit the total amount of cost-sharing that an enrollee is required to pay at point of sale, including deductible payments and the cost-sharing amounts charged once the deductible is met at an amount that does not exceed the net price of the prescription insulin drug.

(b) Nothing in this section shall prevent a health plan company from imposing a cost-sharing requirement that is less than the amount specified in paragraph (a).